U.S. markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.73-0.06 (-0.23%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close23.78
Open23.76
Bid23.25 x 800
Ask23.73 x 800
Day's Range23.43 - 24.23
52 Week Range13.67 - 27.80
Volume2,171,307
Avg. Volume2,310,479
Market Cap7.361B
Beta (5Y Monthly)1.20
PE Ratio (TTM)49.53
EPS (TTM)0.48
Earnings DateFeb 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
47% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates
    Zacks

    Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates

    Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

  • Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
    Business Wire

    Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021

    Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an update on its business. This 2021 financial guidance takes into consideration the anticipated U.S. Food and Drug Administration (FDA) approval and commercial launch of CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma (RCC), which has a Prescription Drug Use Fee Act (PDUFA) target action date of February 20, 2021.

  • 3 Top Biotech Picks for 2021
    Motley Fool

    3 Top Biotech Picks for 2021

    If you want sizzling returns, look no further than the biotech industry. The SPDR S&P Biotech ETF (NYSEMKT: XBI) -- a pretty good barometer for biotechs -- delivered a 48% gain last year. That marked the best performance for the ETF since 2013, when it soared by roughly the same amount.